MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas.
Brain Neoplasms
/ diagnostic imaging
DNA Methylation
DNA Modification Methylases
/ genetics
DNA Repair Enzymes
/ genetics
Glioblastoma
/ diagnostic imaging
High-Throughput Nucleotide Sequencing
Humans
Neoplasm, Residual
O(6)-Methylguanine-DNA Methyltransferase
/ genetics
Prognosis
Retrospective Studies
Tumor Suppressor Proteins
/ genetics
Cutoff value
Glioblastoma
MGMT methylation
Volumetric analysis
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
25
02
2022
accepted:
24
03
2022
pubmed:
11
4
2022
medline:
10
5
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
Although the usefulness of O This retrospective study included newly diagnosed IDH wild-type glioblastoma patients with residual tumor after surgery, followed by local radiotherapy with temozolomide. TVR was defined as the tumor volume at 6 months after the initial chemoradiotherapy administration divided by the tumor volume before the start of therapy. The mean MGMTpm% of 16 CpG islands (74-89) was analyzed using pyrosequencing. We statistically analyzed the correlation between MGMTpm%, TVR, and change in Karnofsky performance status. The study included 44 patients with residual tumors. Thirteen (92.9%) of 14 patients with MGMTpm% ≥ 23.9% showed 50% or more volumetric response, leading to prolonged survival, and 17 (70.8%) of 24 patients with MGMTpm% < 8.2% had progressive disease after initial chemoradiotherapy administration. Three (50.0%) of six patients with MGMTpm% 8.2% to < 23.9% had stable disease or partial response. Evaluation of MGMTpm% by pyrosequencing is important in predicting the volumetric response and prognosis of glioblastoma patients with residual tumors.
Identifiants
pubmed: 35397757
doi: 10.1007/s11060-022-03999-5
pii: 10.1007/s11060-022-03999-5
pmc: PMC9072488
doi:
Substances chimiques
Tumor Suppressor Proteins
0
DNA Modification Methylases
EC 2.1.1.-
MGMT protein, human
EC 2.1.1.63
O(6)-Methylguanine-DNA Methyltransferase
EC 2.1.1.63
DNA Repair Enzymes
EC 6.5.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
561-571Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 21ck0106623h0002
Informations de copyright
© 2022. The Author(s).
Références
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003. https://doi.org/10.1056/NEJMoa043331
doi: 10.1056/NEJMoa043331
pubmed: 15758010
Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-Oncology 12:116–121. https://doi.org/10.1093/neuonc/nop020
doi: 10.1093/neuonc/nop020
pubmed: 20150378
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345
doi: 10.1056/NEJMoa1308345
pubmed: 24552318
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573
doi: 10.1056/NEJMoa1308573
pubmed: 24552317
pmcid: 4201043
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100–1108. https://doi.org/10.1016/S1470-2045(14)70379-1
doi: 10.1016/S1470-2045(14)70379-1
pubmed: 25163906
Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543. https://doi.org/10.1001/jama.2015.16669
doi: 10.1001/jama.2015.16669
pubmed: 26670971
Perry JR, Laperriere N, O’Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP, Trial I (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977
doi: 10.1056/NEJMoa1611977
pubmed: 28296618
Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Buttner R, Pietsch T, Waha A (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368–381. https://doi.org/10.2353/jmoldx.2007.060167
doi: 10.2353/jmoldx.2007.060167
pubmed: 17591937
pmcid: 1899414
Mulholland S, Pearson DM, Hamoudi RA, Malley DS, Smith CM, Weaver JM, Jones DT, Kocialkowski S, Bäcklund LM, Collins VP, Ichimura K (2012) MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. Int J Cancer 131:1104–1113. https://doi.org/10.1002/ijc.26499
doi: 10.1002/ijc.26499
pubmed: 22020830
Arita H, Narita Y, Matsushita Y, Fukushima S, Yoshida A, Takami H, Miyakita Y, Ohno M, Shibui S, Ichimura K (2015) Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas. Brain Tumor Pathol 32:22–30. https://doi.org/10.1007/s10014-014-0186-0
doi: 10.1007/s10014-014-0186-0
pubmed: 24748374
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/JCO.2009.26.3541
doi: 10.1200/JCO.2009.26.3541
pubmed: 20231676
Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M, NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715. https://doi.org/10.1016/S1470-2045(12)70164-X
doi: 10.1016/S1470-2045(12)70164-X
Chan HY, Choi J, Jackson C, Lim M (2021) Combination immunotherapy strategies for glioblastoma. J Neurooncol 151:375–391. https://doi.org/10.1007/s11060-020-03481-0
doi: 10.1007/s11060-020-03481-0
pubmed: 33611705
Brandner S, McAleenan A, Kelly C, Spiga F, Cheng HY, Dawson S, Schmidt L, Faulkner CL, Wragg C, Jefferies S, Higgins JPT, Kurian KM (2021) MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro-Oncology 23:1457–1469. https://doi.org/10.1093/neuonc/noab105
doi: 10.1093/neuonc/noab105
pubmed: 34467991
pmcid: 8408882
Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, Flamion B, DiGuiseppi J, Bierau K, Hegi ME (2008) Validation of real-time methylation-specific PCR to determine O
doi: 10.2353/jmoldx.2008.070169
pubmed: 18556773
pmcid: 2438202
Lattanzio L, Borgognone M, Mocellini C, Giordano F, Favata E, Fasano G, Vivenza D, Monteverde M, Tonissi F, Ghiglia A, Fillini C, Bernucci C, Merlano M, Lo Nigro C (2015) MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens. Int J Biol Markers 30:e208-216. https://doi.org/10.5301/jbm.5000126
doi: 10.5301/jbm.5000126
pubmed: 25588856
Brigliadori G, Foca F, Dall’Agata M, Rengucci C, Melegari E, Cerasoli S, Amadori D, Calistri D, Faedi M (2016) Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. J Neurooncol 128:333–339. https://doi.org/10.1007/s11060-016-2116-y
doi: 10.1007/s11060-016-2116-y
pubmed: 27029617
Chai RC, Liu YQ, Zhang KN, Wu F, Zhao Z, Wang KY, Jiang T, Wang YZ (2019) A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomas. Mod Pathol 32:4–15. https://doi.org/10.1038/s41379-018-0143-2
doi: 10.1038/s41379-018-0143-2
pubmed: 30291347
Håvik AB, Brandal P, Honne H, Dahlback HS, Scheie D, Hektoen M, Meling TR, Helseth E, Heim S, Lothe RA, Lind GE (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med 10:36. https://doi.org/10.1186/1479-5876-10-36
doi: 10.1186/1479-5876-10-36
pubmed: 22390413
pmcid: 3311573
Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Re C (2010) Prognostic value of O
doi: 10.1007/s11060-009-0031-1
pubmed: 19841865
Malley DS, Hamoudi RA, Kocialkowski S, Pearson DM, Collins VP, Ichimura K (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121:651–661. https://doi.org/10.1007/s00401-011-0803-5
doi: 10.1007/s00401-011-0803-5
pubmed: 21287394
Preusser M, Berghoff AS, Manzl C, Filipits M, Weinhausel A, Pulverer W, Dieckmann K, Widhalm G, Wohrer A, Knosp E, Marosi C, Hainfellner JA (2014) Clinical neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin Neuropathol 33:6–14. https://doi.org/10.5414/np300730
doi: 10.5414/np300730
pubmed: 24359605
Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussiere M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O
doi: 10.1002/cncr.27392
pubmed: 22294349
Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T, Haylock B, Walker C (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124–131. https://doi.org/10.1038/sj.bjc.6605127
doi: 10.1038/sj.bjc.6605127
pubmed: 19536096
pmcid: 2713697
Iaccarino C, Nicoli D, Gallo C, Nasi D, Pisanello A, De Berti G, Ghadirpour R, Marcello N, Servadei F (2010) Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy: a preliminary study of ten patients. Acta Neurochir (Wien) 152:1189–1196. https://doi.org/10.1007/s00701-010-0639-0
doi: 10.1007/s00701-010-0639-0
Huang H, Wang FF, Luo S, Chen G, Tang G (2021) Diagnostic performance of radiomics using machine learning algorithms to predict MGMT promoter methylation status in glioma patients: a meta-analysis. Diagn Interv Radiol 27:716–724. https://doi.org/10.5152/dir.2021.21153
doi: 10.5152/dir.2021.21153
pubmed: 34792025
pmcid: 8621632